China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a dual organization structure consisting of group headquarters and business platform headquarters. Its subsidiaries Xuanzhu Biopharm Co., Ltd and Jilin Huisheng Biopharmaceutical Co., Ltd, two biopharmaceutical companies, will establish themselves as the new business platform headquarters.
Subsidiaries’ Focus
Xuanzhu is focused on disease areas of oncology, metabolism, anti-infection, and digestion among others. It has platforms covering small molecules, monoclonal antibodies, bispecific antibodies, fusion proteins, antibody drug conjugates (ADCs), protein degradation, and other fields. Huisheng, meanwhile, is focused on diabetes and its complications. Its product pipeline consists of close to 40 products covering a full range of second-, third-, and fourth-generation insulin and analogs. It has developed SGLT-2, GLP-1, DPP-4, and other products.
Company Strategy
Sihuan will continue to provide strategic guidance and exercise shareholder rights. It will also optimize and integrate its generic business, including shedding the generic drug business and other non-core big health businesses whose performances did not meet expectations.-Fineline Info & Tech
